SCHEMBL6326651

SCHEMBL6326651

N#Cc1c[nH]nc1NC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 5/20 0.35
HPGD P15428 3/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
GAA P10253 4/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HSD17B10 Q99714 2/20 0.34
HTT P42858 1/20 0.34
NLRP3 Q96P20 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
DPYD Q12882 1/20 0.32
LMNA P02545 2/20 0.32
KDM5A P29375 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17651761 0.80 GSK3B (0.48) KDM4EHPGDSMN1; SMN2HTTGSK3A
SCHEMBL17651748 0.77 ABL1 (0.40) GSK3AGSK3B
SCHEMBL29174915 0.77 KMT2A (0.40) GAASMN1; SMN2NPC1RAB9APOLB
SCHEMBL1122974 0.75 S100A9 (0.32) KDM4EALDH1A1HPGDCRHBPCRHR2
SCHEMBL17651740 0.71 CHUK (0.50) KDM4EALDH1A1HPGDGAASMN1; SMN2
SCHEMBL2416315 0.71 CA1 (0.40) DPYD
SCHEMBL20597742 0.70 ALDH1A1 (0.46) KDM4EALDH1A1HPGDGAASMN1; SMN2
SCHEMBL4130221 0.70 GLA (0.40) KDM4EALDH1A1HPGDCRHBPCRHR2
SCHEMBL14828893 0.69 S1PR2 (0.40) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL13834821 0.68 HPGD (0.33) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 KDM4E 360/4885ALDH1A1 338/4885HPGD 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.